Recent debates over skyrocketing drug prices are directly impacting diabetes patients, but it’s an extremely complex situation said Aaron Kowalski, chief mission officer at the Juvenile Diabetes Research Fund (JDRF).
At the heart of the battle is insulin, a vital therapy for more than 6 million Americans. Three major pharmaceutical companies dominate the market, including Novo Nordisk.
The Danish Pharmaceutical company ceased development of its experimental insulin pill in October — a move attributed to poor reimbursement potential.
